USA - NASDAQ:CSBR - US15870P3073 - Common Stock
The current stock price of CSBR is 6.8 USD. In the past month the price increased by 5.92%. In the past year, price increased by 51.96%.
 Symbol   |  Company Name   |  TA   |  FA   |  PE   |  Market Cap   | 
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.22 | 213.30B | ||
| DHR | DANAHER CORP | 27.76 | 153.28B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 154.56 | 46.90B | ||
| A | AGILENT TECHNOLOGIES INC | 26.55 | 41.02B | ||
| IQV | IQVIA HOLDINGS INC | 18.39 | 36.36B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.4 | 28.98B | ||
| WAT | WATERS CORP | 28.26 | 20.57B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.57 | 20.12B | ||
| ILMN | ILLUMINA INC | 27.52 | 18.44B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.54 | 16.69B | ||
| TEM | TEMPUS AI INC | N/A | 15.41B | ||
| ICLR | ICON PLC | 12.8 | 13.13B | 
 Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees.  The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
CHAMPIONS ONCOLOGY INC
One University Plaza,, Suite 307
Hackensack NEW JERSEY 07601 US
CEO: Ronnie Morris
Employees: 210
Phone: 12018088400
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
The current stock price of CSBR is 6.8 USD. The price decreased by -0.58% in the last trading session.
CSBR does not pay a dividend.
CSBR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
CSBR stock is listed on the Nasdaq exchange.
CHAMPIONS ONCOLOGY INC (CSBR) operates in the Health Care sector and the Life Sciences Tools & Services industry.
The Revenue of CHAMPIONS ONCOLOGY INC (CSBR) is expected to grow by 5.84% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 4 / 10 to CSBR. When comparing the yearly performance of all stocks, CSBR is one of the better performing stocks in the market, outperforming 87.1% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to CSBR. There are concerns on the financial health of CSBR while its profitability can be described as average.
Over the last trailing twelve months CSBR reported a non-GAAP Earnings per Share(EPS) of 0.36. The EPS increased by 289.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.19% | ||
| ROA | 9.66% | ||
| ROE | 84.15% | ||
| Debt/Equity | 0.02 | 
7 analysts have analysed CSBR and the average price target is 12.24 USD. This implies a price increase of 80% is expected in the next year compared to the current price of 6.8.
For the next year, analysts expect an EPS growth of -50.13% and a revenue growth 5.84% for CSBR